Cellular Goods PLC (LSE:CBX) said it is seeking further clarification from the UK Food Standards Authority (FSA) on the status of its range of ingestible cannabinoid (CBD) products.
The FSA's current position is that any new products not on sale before February 2020 will not be eligible for the public list and therefore should not be available for sale.
Cellular Goods noted that its branded products are manufactured and supplied by Chanelle McCoy Health, whose products are validated and included on the FSA's permitted list published on 31 March 2022.
"Cellular Goods is currently considering its position pending advice from the company's advisers and is also seeking further clarification on the FSA's stance, considering that these products are identical to the validated products from CMH."
The company added its skincare range, which accounts for the bulk of its overall sales, remains unaffected.